timothy sykes logo
VSTM Stock Draws Bullish Targets As Cancer Data Impress Thumbnail
G Google News

VSTM Stock Draws Bullish Targets As Cancer Data Impress

MATT MONACO•UPDATED OCT. 14, 2026, 7:48 AM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Verastem Inc. stocks have been trading up by 11.03 percent after promising clinical trial news boosted investor optimism.

Key Takeaways

  • New Phase 2 RAMP 201 analyses show avutometinib plus defactinib beating conventional care in recurrent low-grade serous ovarian cancer across KRAS-mutated, wild-type, and Japanese patients.
  • Two-year RAMP 201 follow-up, now in Gynecologic Oncology, confirms durable efficacy and safety backing the FDA accelerated approval in KRAS-mutated disease.
  • Quarterly revenue of $25.1M from the AVMAPKI FAKZYNJA co-pack helps fund VSTM’s VS-7375 KRAS G12D program, which carries FDA Fast Track status.
  • Street coverage has turned firmly positive on VSTM, with RBC Capital, Wolfe Research, and others arguing the stock underprices its growth profile.
  • B. Riley just lifted its VSTM price target from $16 to $19 while maintaining a Buy call, above a Buy-rated $14.67 mean target.

Candlestick Chart

Live Update At 07:47:49 EDT: On Wednesday, October 14, 2026 Verastem Inc. stock [NASDAQ: VSTM] is trending up by 11.03%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

VSTM is acting like a classic biotech in transition: still losing money, but starting to show real revenue traction. The company booked $40.08M in total quarterly revenue, with $25.1M tied to its AVMAPKI FAKZYNJA co-pack in KRAS‑mutated recurrent low‑grade serous ovarian cancer. Gross margin near 86% is typical for branded oncology and gives VSTM plenty of operating leverage once expenses stop growing faster than sales.

Right now, the income statement is still deep in the red. VSTM posted a quarterly net loss of $34.67M and EBITDA of about -$33.22M. Operating cash flow was -$43.91M, so the burn is real. But VSTM ended the quarter with $136.59M in cash, plus a current ratio of 2.3 and quick ratio of 2.1, which buys time to execute.

More Breaking News

On valuation, a price-to-sales ratio around 8.67 and price-to-book over 15 tell traders the market already assigns a premium for future growth, not current earnings. The chart backs that story: VSTM has chopped between roughly $7.50 and $8.60 over the recent stretch, with intraday spikes up toward $9 and $9.20 showing traders are willing to chase momentum when news hits. For short-term trading, this mix of tight range, high beta, and dense news flow is fertile ground.

Why Traders Are Watching VSTM Right Now

VSTM sits at the junction of real-world cancer outcomes and aggressive Wall Street expectations. The core driver is its avutometinib plus defactinib combo in recurrent low‑grade serous ovarian cancer. New RAMP 201 molecular profiling and external control arm work show this regimen delivering “clinically meaningful” responses and significantly better progression‑free survival than conventional care. That outperformance holds across KRAS‑mutated and KRAS wild‑type disease, and even in a Japanese cohort.

For traders, that matters more than any pitch deck. It signals VSTM has a therapy that is not just approved for a narrow KRAS‑mutant slice, but backed by data that support label and market expansion into a broader RAS/MAPK‑driven population and potentially into Japan. Bigger addressable market, more scripts, more potential revenue — that is the trade.

The two‑year RAMP 201 follow‑up, now peer‑reviewed in Gynecologic Oncology, adds another layer. Long‑term durability and safety are holding up, which reduces the risk that payors or doctors back away later. Publication also makes it easier for VSTM to push for inclusion in treatment guidelines, a quiet but powerful driver of adoption.

At the same time, VSTM is not a one‑asset story. The company is advancing VS‑7375, an oral KRAS G12D inhibitor with FDA Fast Track in pancreatic cancer and non‑small cell lung cancer, and plans to share Phase 2 TARGET‑D data. If that program shows solid efficacy, traders will start to treat VSTM as a multi‑pillar oncology platform.

Wall Street is already leaning that way. RBC Capital says VSTM’s current share price does not reflect its growth potential, pointing to an A+F commercial franchise that is approaching profitability by year‑end. Wolfe Research initiated coverage with an Outperform, and B. Riley just raised its VSTM target from $16 to $19 while maintaining Buy. With the Street’s mean target still at $14.67, traders are staring at a consensus that expects upside versus current prices.

Even smaller signals support a scaling story. VSTM granted 380,500 RSUs and new options to incoming employees under Nasdaq’s inducement rules. Yes, that adds some dilution. But it also shows the company is building out commercial and clinical talent to support growth — something momentum traders watch when gauging whether a launch is real.

Conclusion

For active traders, VSTM is a textbook “story meets numbers” setup. The AVMAPKI FAKZYNJA co‑pack is already generating $25.1M in quarterly revenue, backed by strong RAMP 201 data that now include external control arm comparisons and long‑term follow‑up in a peer‑reviewed journal. That is real‑world traction in a rare oncology niche where competitors are limited and pricing power is traditionally strong.

At the same time, VSTM’s financials still scream “development‑stage biotech.” Losses remain heavy, cash burn is meaningful, and key profitability metrics are negative across the board. The bull case is simple: if revenue from the avutometinib plus defactinib combo keeps growing and VS‑7375 delivers, those losses can narrow quickly and the current premium valuation starts to look justified.

The tape reflects this tug‑of‑war. VSTM has been range‑bound near the high‑$7s and low‑$8s, with sharp intraday spikes toward $9+ on news. That kind of action rewards traders who prepare levels, react fast, and respect risk. As Tim Sykes likes to hammer home, “the pattern matters, but cutting losses quickly matters even more.” As millionaire penny stock trader and teacher Tim Sykes says, “Cut losses quickly, let profits ride, and don’t overtrade.”. For anyone trading VSTM, that mindset is key: study the clinical and analyst catalysts, map the chart, and always treat this as an educational and research-driven setup, not a guarantee of future gains.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”